Travere Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for TVTX, updated each market day.
TVTX AI Sentiment
AI predicts Travere Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Travere Therapeutics, Inc. Common Stock
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Sector
Exchange
Market Cap
$3,770,535,725
Cap Tier
Employees
497
Headquarters
SAN DIEGO, CA
Listed Since
July 23, 2003
Website
TVTX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TVTX Volatility
Travere Therapeutics, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
